These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 17047391

  • 1. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P.
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [Abstract] [Full Text] [Related]

  • 2. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A, Jaquet P, Brue T, Barlier A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):206-13. PubMed ID: 18241980
    [Abstract] [Full Text] [Related]

  • 3. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD.
    J Endocrinol Invest; 2005 May 14; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD.
    Eur J Endocrinol; 2005 Jul 14; 153(1):135-41. PubMed ID: 15994755
    [Abstract] [Full Text] [Related]

  • 5. [New medical treatments in pituitary adenomas].
    Drutel A, Caron P, Archambeaud F.
    Ann Endocrinol (Paris); 2008 Sep 14; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau JP, Saveanu A, Gunz G, Dufour H, Jaquet P.
    Endocr Relat Cancer; 2008 Jun 14; 15(2):583-96. PubMed ID: 18509006
    [Abstract] [Full Text] [Related]

  • 7. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.
    Clin Endocrinol (Oxf); 2012 Mar 14; 76(3):407-14. PubMed ID: 21848909
    [Abstract] [Full Text] [Related]

  • 8. New SRIF analogs in the control of human pituitary adenomas: perspectives.
    Jaquet P, Saveanu A, Barlier A.
    J Endocrinol Invest; 2005 Mar 14; 28(5 Suppl):14-8. PubMed ID: 16114269
    [Abstract] [Full Text] [Related]

  • 9. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM.
    Sci Rep; 2017 Feb 09; 7():42002. PubMed ID: 28181484
    [Abstract] [Full Text] [Related]

  • 10. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2002 Dec 09; 87(12):5545-52. PubMed ID: 12466351
    [Abstract] [Full Text] [Related]

  • 11. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan 09; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 12. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A, Mantovani G, Spada A.
    Mol Cell Endocrinol; 2008 May 14; 286(1-2):180-6. PubMed ID: 17913341
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S.
    Endocr J; 2004 Apr 14; 51(2):227-36. PubMed ID: 15118275
    [Abstract] [Full Text] [Related]

  • 14. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC.
    J Mol Endocrinol; 2005 Oct 14; 35(2):333-41. PubMed ID: 16216913
    [Abstract] [Full Text] [Related]

  • 15. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP.
    J Clin Endocrinol Metab; 2010 May 14; 95(5):2497-502. PubMed ID: 20233783
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
    Gruszka A, Culler MD, Melmed S.
    Mol Cell Endocrinol; 2012 Oct 15; 362(1-2):104-9. PubMed ID: 22705877
    [Abstract] [Full Text] [Related]

  • 17. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May 15; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

  • 18. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW.
    J Endocrinol Invest; 2005 May 15; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T, Mohamed A, Graillon T, Roche C, Defilles C, Germanetti AL, Couderc B, Figarella-Branger D, Enjalbert A, Barlier A, Saveanu A.
    Mol Cell Endocrinol; 2012 May 15; 355(1):106-13. PubMed ID: 22348806
    [Abstract] [Full Text] [Related]

  • 20. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD.
    J Physiol Pharmacol; 2007 Mar 15; 58(1):179-88. PubMed ID: 17440235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.